Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pancreatic Neoplasms × pegilodecakin × Clear all

Phase

Phase 3 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 68 Fluorouracil 28 Oxaliplatin 18 Leucovorin 18 Capecitabine 13 130-nm albumin-bound paclitaxel 12 Irinotecan 9 Albumin-Bound Paclitaxel 9 irinotecan sucrosofate 7 Radiotherapy 6 Taxes 5 Erlotinib Hydrochloride 5 folfirinox 4 rubitecan 3 Surgical Procedures, Operative 3 Specimen Handling 3 Pancreaticojejunostomy 3 Neoadjuvant Therapy 3 Drug Therapy 3 Cisplatin 3 ruxolitinib 2 masitinib 2 dehydroftorafur 2 Saline Solution 2 S 1 (combination) 2 Paclitaxel 2 GV1001 peptide 2 Fentanyl 2 Chemotherapy, Adjuvant 2 Bevacizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02923921 2020-10-19

Sequoia

Eli Lilly and Company

Phase 3 Completed

567 enrolled 17 charts

Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡